Data show most older adults with newly diagnosed AML expect stable or improving physical function, while oncologists ...
Updated systematic review finds GLP-1 therapies deliver substantial weight loss, with newer multiagonists and oral options ...
Coexisting emphysema may be an important phenotype in patients with fibrotic interstitial lung disease (ILD), tied to ...
The 9 companies—Alcon, Astellas Pharma, BeOne Medicines, BridgeBio, CSL, Kyowa Kirin, Sun Pharma, Teva Pharmaceuticals, and ...
Colborn noted CMS estimates that approximately 13 million individuals could be eligible for GLP-1 therapy for weight loss ...
Selinexor achieved a 35% or greater spleen volume reduction in 17% of patients at week 24, and in 23% at any point during ...
FUSION trial data published show FFRCT added to CCTA safely cut unnecessary catheterizations. One-year results from the ...
New multi-center registry data confirm MAC as the dominant cause of NTM pulmonary disease, while culture conversion with standard therapy still fails in nearly half of patients. This episode, "New ...
Population Health, Equity & Outcomes is a quarterly publication dedicated to providing a platform for the exchange of research, policy analysis, and insights that aim to improve health outcomes and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results